Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ORIC Pharmaceuticals Inc
ORIC | US
11.65
USD-2.06
-15.03%
ORIC | US
About ORIC Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
11.65
Open
11.81
High
12.95
Low
10.98
ORIC Pharmaceuticals Inc. a clinical-stage biopharmaceutical company discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533 an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944 an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114 a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco California.
View LessORIC | US
Risk
88.5
Sharpe
0.53
Luna's Score
37/100
Recommendation
Sell
Luna says (ORIC | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
111.0%1 month
88.5%3 months
78.7%6 months
73.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.13
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.13
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-124.06M
MarketCap
821.82M
MarketCap(USD)
821.82M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-38.79
Short ratio
23.39
Short perc.
17.65
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.27
Range1M
4.31
Range3M
6.42
Volumes: Market Activity
Rel. volume
2.54
Price X volume
47.45M
